Novartis-backed GenSight gets cash for gene therapy launch – FierceBiotech
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … French Biotech Raises Over €22M to Launch a Gene Therapy to Restore SightLabiotech.eu (blog) |
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … French Biotech Raises Over €22M to Launch a Gene Therapy to Restore SightLabiotech.eu (blog) |
|
CRISPR crew’s lab test spotlights lead program in sickle cell disease, beta-thalassemia
Endpoints News CRISPR/Cas9 tech is still at a very early stage of development. But one of the top biotechs looking to make a breakthrough in the clinic got a chance today to explain why one of its preclinical studies helps demonstrate gene editing’s promise in … European Hematology Association: Treating Sickle Cell Disease …PR Newswire (press release) |
|
Sarepta Signs Gene Therapy R&D Deal for DMD
Drug Discovery & Development Genethon specializes in a micro-dystrophin gene therapy approach that can target the majority of patients with DMD, according to the announcement. The organization has demonstrated proof-of-concept of their program through a robust gene expression in a … |
|
Immunotherapy Safely Treats Advanced Squamous Cell Carcinoma
Cancer Network Immunotherapy Safely Treats Advanced Squamous Cell Carcinoma. News | June 23, 2017 | Skin Cancer (Nonmelanoma). By Mark L. Fuerst. A fully human anti–programmed death 1 (PD-1) monoclonal antibody is safe and effective for patients with … |
Labiotech.eu (blog) |
French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight
Labiotech.eu (blog) Gensight Biologics has announced a capital increase that totals €22.5M and will support the launch of its gene therapy for blindness in Europe and the US. Gensight has decided to give an additional financial push to its lead candidate, GS010, a gene … |
Scicasts (press release) (blog) |
Firefly Gene Illuminates Ability of Optimized CRISPR–Cpf1 to Efficiently Edit Human Genome
Scicasts (press release) (blog) Professor Michael Farzan, co-chair of TSRI’s Department of Immunology and Microbiology, and TSRI Research Associate Guocai Zhong improved the efficiency of the CRISPR–Cpf1 gene editing system by incorporating guide RNAs with “multiplexing” … |